Table 1.

Mean pharmacokinetic values determined for rats and cynomolgus macaques following single intravenous administration of VX15/2503

RataCynomolgus macaqueb
DoseCmaxAUC0–tHalf-lifeCmaxAUC0-tHalf-life
(mg/kg)(μg/mL)(μg/h/mL)(d)(h)(μg/mL)(μg/h/mL)(d)(h)
0.01NCcNCNCNC0.0750.312NCNCc
0.11.9911.400.13.52.9823.21NCNC
1.034.14834.71.227.840.81,898NCNC
10317.727,4314.4105.734237,423NCNC
1003,305488,19410.3246.23,785725,6729.0215

NOTE: Rat PK data were derived from a single compartment two-phase pharmacokinetic modeling with male and female data combined. Antibody was administered intravenously over a period of roughly 5 minutes; 3 animals of each gender were in each dose group. Similar results were obtained following separate analyses of data from males and from females. Primate PK data were derived from a noncompartmental analysis with 2 animals of each gender in each dose group. Data shown are for males and females combined; similar results were obtained following separate analyses of data from males and females.

  • aBased on single compartment two-phase pharmacokinetic modeling. Three animals of each gender were included in each dose group.

  • bBased on noncompartmental analysis with 2 animals of each gender in each dose group.

  • cInsufficient data to perform the calculation.